Sunitinib-platinum (IV) prodrug-1

Sunitinib-platinum (IV) prodrug-1 (Complex A) is a Cisplatin-based Pt (IV) prodrug designed to be reduced to active Pt (II) in intracellular reductive conditions, while concurrently releasing a sunitinib derivative with tyrosine kinase inhibitor (TKI) activity. This compound exhibits remarkable cytotoxicity against renal cell carcinoma (RCC), inducing DNA crosslinking and apoptosis. It inhibits VEGFR/PDGFR signaling pathways, thereby suppressing tumor growth and angiogenesis, and can be used for studying RCC.